Edwards' TAVR Cuts Risk Of Death Or Heart Failure Events In Moderate Aortic Stenosis Trial

Edwards Lifesciences reported Phase 3 PROGRESS trial results showing TAVR was superior to clinical surveillance in patients with moderate aortic stenosis who had features associated with higher disease-progression risk. The supplied article text ends before providing further trial details or numerical results.